Drug Search Results
More Filters [+]

EC-90

Alternative Names: ec-90, ec90, ec 90
Latest Update: 2024-05-29
Latest Update Note: News Article

Product Description

Folate immune (EC90 vaccine with GPI-0100 adjuvant followed by EC17) is a novel folate-targeted hapten immunotherapy designed to exploit the overexpression of folate receptors on renal cell carcinoma (RCC) cells. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24714357/)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EC-90

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PICC&PAC

N/A

Completed

Cognitive Dysfunction|Venous Thrombosis|Breast Cancer

2021-02-01

Recent News Events